ultra-rapid-acting recombinant human insulin (BIOD-123) - Albireo
Biodel: BIOD-123 Study 3-201 Top Line Data Conference Call (Biodel) - Sep 10, 2013 - P2, N=130; "HbA1c and Insulin Doses During 0-6 Weeks (Titration Period) Compared to 6-18 Weeks (Stable Dosing Period); "Study 3-201: BIOD-123 Phase 2 Trial Preliminary Results" 
P2 data Diabetes
http://investor.biodel.com/eventdetail.cfm?eventid=134355
 
Sep 10, 2013
 
.
 
6923c340-a716-4768-8fce-e2eb0c42cc6e.jpg